


APPROVED	O.G. F(1)	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621
 PHARMACEUTICAL COMPOSITION...
 Filed: January 23, 2001
 Waddell A. Biggart
 202-293-7060
 1 of 6

09/744328

1/6

Fig.1




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621
PHARMACEUTICAL COMPOSITION...
Filed: January 23, 2001
Waddell A. Biggart
202-293-7060
2 of 6

U9/744328

2/6

Fig.2




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621
 PHARMACEUTICAL COMPOSITION...
 Filed: January 23, 2001
 Waddell A. Biggart
 202-293-7060
 3 of 6

09/744328

3/6


Fig.3



- without addition of TGF- β and galectin-3
- without addition of TGF- β , and with addition of 50 μ g/ml of galectin-3
- ▼--- with addition of 0.4 ng/ml of TGF- β , and without addition of galectin-3
- ▽--- with addition of 0.4 ng/ml of TGF- β and 50 μ g/ml of galectin-3

4/6

Fig. 4




APPROVED	O.G. FIG.
BY	CLASS SUBCLASS
DRAFTSMAN	

SASAKI et al Q62621
 PHARMACEUTICAL COMPOSITION...
 Filed: January 23, 2001
 Waddell A. Biggart
 202-293-7060
 5 of 6

U9/744328

5/6

Fig. 5



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SASAKI et al Q62621
PHARMACEUTICAL COMPOSITION...
Filed: January 23, 2001
Waddell A. Biggart
202-293-7060
6 of 6

U9/744328

6/6

Fig. 6

